What is TAK stock price today?

TAK (Takeda Pharmaceutical Co Ltd) stock is trading at $17.85 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is TAK stock going up or down today?

TAK stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy TAK stock now?

The decision to buy TAK depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is TAK a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for TAK based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is TAK stock overvalued or undervalued?

TAK currently trades at a P/E ratio of 81.14, which may indicate premium valuation. Our DCF calculator provides intrinsic value estimates to help determine if TAK is fairly priced.

What is TAK's P/E ratio?

TAK has a price-to-earnings (P/E) ratio of 81.14, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is TAK's market cap?

TAK (Takeda Pharmaceutical Co Ltd) has a market capitalization of $56.39 billion, making it a mid-cap stock.

What is TAK's price to book ratio?

TAK trades at a price-to-book (P/B) ratio of 1.17, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does TAK pay dividends?

Yes, TAK pays dividends with a current yield of 0.04%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is TAK's dividend yield?

TAK's dividend yield is 0.04%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is TAK stock a good long-term investment?

TAK's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is TAK's revenue growth rate?

TAK has shown revenue growth of 0.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, TAK is profitable with a profit margin of 0.0%. This indicates the company generates 0.0 cents of profit for every dollar of revenue.

What are the risks of investing in TAK?

Key risks for TAK include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does TAK compare to its competitors?

Compare TAK to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize TAK's performance and positioning.

What is TAK's stock price target for 2026?

Our AI model provides price targets for TAK based on fundamental analysis: Bull case $23.21 (+30%), Base case $20.53 (+15%), Bear case $16.07 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about TAK?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for TAK. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is TAK's next earnings report?

TAK reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

TAK - Takeda Pharmaceutical Co Ltd

NYSE * Health Care * Pharmaceuticals

$17.85

+$0.00 (+0.00%)

About Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan.

TAK Key Statistics

Market Cap

$56.39B

P/E Ratio

81.14

P/B Ratio

1.17

EPS

$0.22

Dividend Yield

0.04%

Revenue Growth

+0.0%

Profit Margin

0.0%

Employees

47,455

How TAK Compares to Peers

TAK trades at a premium valuation vs peers (highest P/E)

TAK is the smallest among peers, which may offer higher growth potential

P/E Rank

of 2

Margin Rank

of 2

Growth Rank

of 2

Size Rank

of 2

Company	Market Cap	P/E	Growth	Margin	Compare
TAK(This stock)	$56.39B	81.1	0%	0.0%	-
AMZNAmazon Com	$2.67T	34.6	0%	0.1%	vs AMZN

Takeda Pharmaceutical Co Ltd Company Information

Headquarters: Japan
Website: www.takeda.com
Sector: Health Care
Industry: Pharmaceuticals

About Takeda Pharmaceutical Co Ltd

TAK Key Statistics

How TAK Compares to Peers

Takeda Pharmaceutical Co Ltd Company Information

Upcoming Events for TAK